AACR 2025 preview – distressed biotechs seek redemption
Ikena, Senti and others look to clinical presentations at AACR.
Nothing like Hippo for cooling investor enthusiasm
Ikena is savaged in a bear market after reporting zero remissions in a dose-escalation trial of its lead asset.
